Web Analytics Made Easy - Statcounter

top of page

Multiple Myeloma Clinical Trials - @ University of Miami,
Sylvester Comprehensive Cancer Center

Multiple Myeloma Clinical Trials at University of Miami, Sylvester Comprehensive Cancer Center

CD38-Targeted ImmunoPET of Myeloma

CD38-Targeted ImmunoPET of Myeloma

REGN5458

REGN5458

MagnetisMM-4

MagnetisMM-4

CD38-Targeted ImmunoPET of Myeloma

CD38-Targeted ImmunoPET of Myeloma

1/11

Multiple Myeloma Clinical Trials Currently Recruiting

NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets

2022 - (R) NCT05308654

Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets

NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

2021 (R) NCT04814615

Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM

2021 - (R) NCT05090566

Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM

NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

2021 - (R) NCT05024045

Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma

2020 (R) NCT04582539

Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma

NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)

2020 (R) NCT04270409

Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)

NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)

2020 (R) NCT04268498

Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)

NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC

2019 (R) NCT04071457

Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC

NCT04017130: Phase 1: Study to Evaluate the Safety, Tolerability, Pharmak & Efficacy of MT-0169 RRMM

2019 (R) NCT04017130

Phase 1: Study to Evaluate the Safety, Tolerability, Pharmak & Efficacy of MT-0169 RRMM

NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)

2019 (R) NCT03901963

Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)

NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM

2018 - (R) NCT03761108

Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM

NCT03582033: Phase 1 - A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

2018 - (R) NCT03582033

Phase 1 - A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

United States - Myeloma Clinical Trials | MCT Index (themyelomaclinicaltrials.com)

bottom of page